FLT3 and acute myeloid leukemia: Suppression of glucose-6-phosphate dehydrogenase and pharmacological inhibition of FLT3 with lestaurtinib induced a significant anti-leukaemic effect in AML cells with FLT3-ITD and was identified as a potential therapeutic strategy (53).